Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.109920 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.109920 32534337!7263256!32534337     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 144 (ä): 109920 Nephropedia Template TP {{tp|p=32534337|t=2020. Diacerein: A potential multi-target therapeutic drug for COVID-19 |pdf=|usr=}}{{32534337}} gab.com Text Diacerein: A potential multi-target therapeutic drug for COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32534337 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 19 (COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds its host cell receptor, angiotensin-converting enzyme 2 (ACE2), through the viral spike (S) protein. The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue. In addition, cardiac symptoms, including fulminant myocarditis, are frequent in patients in a severe state of illness. Diacerein (DAR) is an anthraquinone derivative drug whose active metabolite is rhein. Different studies have shown that this compound inhibits the IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF-alpha, NF-kappaB and NALP3 inflammasome pathways. The antiviral activity of rhein has also been documented. This metabolite prevents hepatitis B virus (HBV) replication and influenza A virus (IAV) adsorption and replication through mechanisms involving regulation of oxidative stress and alterations of the TLR4, Akt, MAPK, and NF-kappaB signalling pathways. Importantly, rhein inhibits the interaction between the SARS-CoV S protein and ACE2 in a dose-dependent manner, suggesting rhein as a potential therapeutic agent for the treatment of SARS-CoV infection. Based on these findings, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control hyperinflammatory conditions by multi-faceted cytokine inhibition and by reducing viral infection. Twit Text FOAVip Diacerein: A potential multi-target therapeutic drug for COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32534337 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32534337 #FOAvip English Wikipedia <ref>{{Cite pmid|32534337}}</ref> Diacerein: A potential multi-target therapeutic drug for COVID-19 #MMPMID32534337 de Oliveira PG; Termini L; Durigon EL; Lepique AP; Sposito AC; Boccardo E Med Hypotheses 2020[Nov]; 144 (ä): 109920 PMID32534337show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 19 (COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds its host cell receptor, angiotensin-converting enzyme 2 (ACE2), through the viral spike (S) protein. The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue. In addition, cardiac symptoms, including fulminant myocarditis, are frequent in patients in a severe state of illness. Diacerein (DAR) is an anthraquinone derivative drug whose active metabolite is rhein. Different studies have shown that this compound inhibits the IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF-alpha, NF-kappaB and NALP3 inflammasome pathways. The antiviral activity of rhein has also been documented. This metabolite prevents hepatitis B virus (HBV) replication and influenza A virus (IAV) adsorption and replication through mechanisms involving regulation of oxidative stress and alterations of the TLR4, Akt, MAPK, and NF-kappaB signalling pathways. Importantly, rhein inhibits the interaction between the SARS-CoV S protein and ACE2 in a dose-dependent manner, suggesting rhein as a potential therapeutic agent for the treatment of SARS-CoV infection. Based on these findings, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control hyperinflammatory conditions by multi-faceted cytokine inhibition and by reducing viral infection. |*COVID-19 Drug Treatment[MESH] |Angiotensin-Converting Enzyme 2/drug effects/metabolism[MESH] |Animals[MESH] |Anthraquinones/*therapeutic use[MESH] |Anti-Inflammatory Agents/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19/metabolism/virology[MESH] |Cytokines/metabolism[MESH] |Drug Evaluation, Preclinical[MESH] |Host Microbial Interactions/drug effects[MESH] |Humans[MESH] |Male[MESH] |Mice, Inbred C57BL[MESH] |Models, Biological[MESH] |Oxidation-Reduction/drug effects[MESH] |Pandemics[MESH] |Receptors, Coronavirus/drug effects/metabolism[MESH] |SARS-CoV-2/drug effects[MESH] |Signal Transduction/drug effects[MESH]Diacerein: A potential multi-target therapeutic drug for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing